Determination of Blood Tumor Cells

Completed

• Conditions: Abnormalities Cell Epithelial; Leukemia, Lymphocytic, Chronic, B-Cell

• Registration Number: NCT04290923
• Lead Sponsor: University of Zurich

Brief Summary

Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .

Detailed Description

Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.

Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).

Study Timeline

• Study Start: 2017-10-01
• Study First Submitted: 2020-02-27
• Study First Submitted QC: 2020-02-28
• Study First Posted: 2020-03-02
• Primary Completion: 2022-10-26
• Study Completion: 2022-12-30
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-09
• Last Update Posted: 2023-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)

Exclusion Criteria

Inability to understand the language of the center (German)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of CTC / lymphocytes removed	1 day

Trial Locations

Locations (1)

University Hospital Zurich; 🇨🇭 Zurich, Switzerland